ARV-102 is an oral, brain-penetrant investigational PROTAC designed to degrade LRRK2, which is a large, multidomain scaffolding kinase. Increased activity, scaffolding, and expression of LRRK2 have ...
We talk to Nasuni founder and chief technology officer (CTO) Andres Rodriguez about the characteristics needed from storage to make optimal use of unstructured data in the enterprise, as well as the ...
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...
Correction: After publishing, Red Hat confirmed that it was a breach of one of its GitLab instances, and not GitHub. Title and story updated. An extortion group calling itself the Crimson Collective ...
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, ...
A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...
1 Day CDR -5.49% DJIA -1.90% S&P 500 -2.71% Consumer Goods 0.14% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback